Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...
Coloplast's stock price has declined by 25% since April 2023, making it more attractive but still overvalued based on fundamentals and valuation multiples. Recent quarterly results show revenue growth ...
Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...
COPENHAGEN, July 7 (Reuters) - Coloplast COLOb.CO has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up to $1.3 billion, ...
Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral ...
Coloplast A/S is acquiring Kerecis hf, a closely held Icelandic maker of fish-skin dressings to treat human wounds, for an enterprise value of up to $1.3 billion. Coloplast is making a $1.2 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback